CD274 and neoplasm: In fact, acquired resistance to anti-PD-1/PD-L1 therapy by PD-L1-carrying EVs has already been demonstrated in several solid-tumor entities [71] and it is speculated that PD-L1 presented by EVs may preferentially bind immunotherapeutic antibodies and thereby act as a “sink” to divert them away from the tumor cells [72].